title: Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma.
abstract: Advanced hepatocellular carcinoma (HCC) remains a fatal disease even in the era of targeted therapies. Intra-arterial chemotherapy (IACT) can provide therapeutic benefits for patients with locally advanced HCC who are not eligible for local therapies or are refractory to targeted therapies. The aim of this retrospective study was to analyze the effect of IACT with cisplatin and doxorubicin on advanced HCC.
  
  
  METHODS
  Patients with advanced HCC who were not eligible for local therapies or were refractory to sorafenib received doxorubicin (50 mg/m(2)) and cisplatin (50 mg/m(2)) infusions into the liver via the transhepatic artery. Between January 2005 and December 2011, a total of 50 patients with advanced HCC received this treatment regimen. The overall response rate (ORR) was 22% in all treated patients. In patients who received at least 2 cycles of IACT, the ORR was 36.7%, and the disease control rate was 70%. Survival rate differed significantly between patients who received only one cycle of IACT (group I) and those who received several cycles (group II). The median progression-free survival was 1.3 months and 5.8 months in groups I and II, respectively (P < 0.0001). The median overall survival was 8.3 months for all patients and was 3.1 months and 12.0 months in groups I and II, respectively (P < 0.0001). The most common toxicity was alopecia. Four patients developed grade 3 or 4 leukopenia. Worsening of liver function, nausea, and vomiting were uncommon side effects. This study demonstrated clinical efficacy and tolerable side effects of repeated IACT with doxorubicin and cisplatin in advanced HCC. Our regimen can be an alternative choice for patients with adequate liver function who do not want to receive continuous infusion of IACT.
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan.
authors: Ming-Chun
authors: MC
authors: Ma
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan ; College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan.
authors: Yen-Yang
authors: YY
authors: Chen
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan ; College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan.
authors: Shau-Hsuan
authors: SH
authors: Li
authors: College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan ; Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan.
authors: Yu-Fan
authors: YF
authors: Cheng
authors: College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan ; Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan.
authors: Chih-Chi
authors: CC
authors: Wang
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan ; College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan.
authors: Tai-Jan
authors: TJ
authors: Chiu
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan ; College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan.
authors: Sung-Nan
authors: SN
authors: Pei
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan.
authors: Chien-Ting
authors: CT
authors: Liu
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan ; College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan.
authors: Tai-Lin
authors: TL
authors: Huang
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan ; College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan.
authors: Chen-Hua
authors: CH
authors: Huang
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan.
authors: Yu-Li
authors: 0000-0002-1289-473X
authors: YL
authors: Su
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan.
authors: Yen-Hao
authors: YH
authors: Chen
authors: College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan ; Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan.
authors: Sheng-Nan
authors: 0000-0002-5493-4752
authors: SN
authors: Lu
authors: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan ; College of Medicine, Chang Gung University, Kaohsiung 333, Taiwan.
authors: Kun-Ming
authors: KM
authors: Rau
mesh_terms: D000328:Adult; D000368:Aged; D000792:Angiography; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D002945:Cisplatin